Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oric Pharmaceuticals, Inc. Director's Dealing 2021

May 25, 2021

32131_dirs_2021-05-24_b3edada5-cabd-4682-a651-c323df5c2766.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-05-20

Reporting Person: Heyman Richard A. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-20 Common Stock S 700 $25.0829 Disposed 220526 Indirect
2021-05-21 Common Stock S 600 $25.25 Disposed 219926 Indirect
2021-05-24 Common Stock S 100 $25.00 Disposed 219826 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 12500 Direct

Footnotes

F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by RAHD Capital, LLC.

F2: Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $25.00 to $25.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

F4: Represents the weighted average share price of an aggregate total of 600 shares sold in the price range of $25.18 to $25.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.